Education
About Us
Working with TipRanks
Follow Us
Elite Pharmaceuticals (ELTP)
OTHER OTC:ELTP
RESEARCH TOOLSreports
Top Page
Elite Pharmaceuticals
(OTC:ELTP)
46Neutral
Elite Pharmaceuticals (ELTP) vs. S&P 500 (SPY)
Market Cap
$454.44M
Dividend YieldN/A
Average Volume (3M)892.73K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth47.93%
EPS Growth-208.44%
CountryUS
Employees64
SectorHealthcare
Sector Strength73
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,068,273,100
10 Day Avg. Volume1,504,549
30 Day Avg. Volume892,733
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.00
Price to Cash Flow (P/CF)-115.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Elite Pharmaceuticals Business Overview & Revenue Model
Company DescriptionElite Pharmaceuticals, Inc. (ELTP) is a specialty pharmaceutical company engaged in the development and manufacturing of oral, controlled-release products, and generic pharmaceuticals. The company operates in the healthcare and pharmaceutical sectors, focusing on niche drug delivery systems for the treatment of pain and other conditions. Elite Pharmaceuticals leverages its proprietary technology to create and market a diverse portfolio of products, primarily targeting the generic drug market.
How the Company Makes MoneyElite Pharmaceuticals generates revenue through the sale of its pharmaceutical products, which include both branded and generic formulations. The company's primary revenue streams come from the manufacturing and distribution of controlled-release tablets and capsules. Elite Pharmaceuticals also engages in licensing agreements and strategic partnerships to enhance its product offerings and expand its market reach. These collaborations often involve revenue-sharing arrangements or royalty payments based on sales performance. Additionally, Elite may receive milestone payments and upfront fees from partners for co-development or commercialization of pharmaceutical products. The company's focus on developing cost-effective and high-quality generic drugs allows it to capture market share and compete effectively in the pharmaceutical industry.
Elite Pharmaceuticals Financial Statement Overview
Summary
Elite Pharmaceuticals shows revenue growth but struggles with profitability, indicated by negative net income and EBITDA. The balance sheet displays low leverage, providing some stability; however, declining equity is a potential risk. Cash flow remains positive, but converting profits to cash is challenged by net losses.Income Statement
The TTM (Trailing-Twelve-Months) data shows a negative net income and EBITDA, indicating profitability challenges. Although revenue has grown from previous periods, the net profit margin is negative at -25.7%, which is concerning. The EBIT margin is decent at 17.4%, but the company's ability to convert revenue into actual profit remains weak.45
Neutral
Balance Sheet
The company's balance sheet reflects moderate stability with a debt-to-equity ratio of 0.22, indicating low financial leverage. The equity ratio stands at 40.2%, signifying a reasonable equity buffer. However, the decline in stockholders' equity from the previous period is a potential risk factor.60
Neutral
Cash Flow
The TTM data highlights positive operating cash flow but a significant drop in free cash flow growth compared to previous periods. The free cash flow to net income ratio is less relevant due to negative net income, indicating challenges in translating accounting profits to cash.50
Neutral
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 70.00M | 56.63M | 34.16B | 32.26M | 25.38M | 17.99M | Gross Profit |
| 30.53M | 26.36M | 16.59B | 14.80M | 11.87M | 7.98M | EBIT |
| 12.18M | 10.79M | 2.03B | 5.07M | 2.10M | -2.29M | EBITDA |
| -13.08M | 2.58M | 6.43M | 6.27M | 5.93M | -371.88K | Net Income Common Stockholders |
| -17.99M | 20.11M | 4.41B | 8.90M | 5.09M | -2.24M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 8.29M | 7.11M | 7.83M | 8.54M | 3.19M | 1.13M | Total Assets |
| 90.76M | 83.65M | 40.90M | 35.15M | 26.19M | 24.96M | Total Debt |
| 8.00M | 11.74M | 3.89M | 2.78M | 2.38M | 4.03M | Net Debt |
| -293.81K | 4.63M | -3.94M | -5.75M | -814.26K | 2.90M | Total Liabilities |
| 54.31M | 26.07M | 11.94M | 9.93M | 10.04M | 14.30M | Stockholders Equity |
| 36.45M | 57.58M | 28.96M | 25.22M | 16.15M | 10.66M |
| Cash Flow | Free Cash Flow | ||||
| 4.32M | -4.09M | -2.40M | 6.01M | 2.86M | -1.83M | Operating Cash Flow |
| 5.60M | -3.28M | 3.34M | 6.51M | 3.19M | -1.79M | Investing Cash Flow |
| -2.05M | -809.65K | -5.74M | -498.57K | -262.78K | -34.95K | Financing Cash Flow |
| -1.05M | 3.39M | 1.70M | -667.13K | -869.83K | 689.54K |
Elite Pharmaceuticals Technical Analysis
Negative
0.42
Price Trends
0.46
Negative
0.50
Negative
0.42
Negative
Market Momentum
-0.02
Negative
47.16
Neutral
84.77
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTP, the sentiment is Negative. The current price of 0.42 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.46, and below the 200-day MA of 0.42, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.16 is Neutral, neither overbought nor oversold. The STOCH value of 84.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTP.
Elite Pharmaceuticals Risk Analysis
Elite Pharmaceuticals disclosed 41 risk factors in its most recent earnings report. Elite Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elite Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
50 Neutral | $411.66M | ― | -136.30% | ― | -36.95% | -22.68% | |
50 Neutral | $5.51B | 2.95 | -43.70% | 2.78% | 16.94% | 3.59% | |
46 Neutral | $454.44M | ― | -43.41% | ― | 47.93% | -208.44% | |
46 Neutral | $467.88M | ― | -44.15% | ― | -60.83% | 14.13% | |
41 Neutral | $304.77M | ― | -28.19% | ― | ― | -48.01% | |
40 Underperform | $469.72M | ― | ― | -25.10% | -7.06% | ||
27 Underperform | $418.29M | ― | -68.01% | ― | ― | 26.24% |
* Healthcare Sector Average
Performance Comparison
ELTP
Elite Pharmaceuticals
0.42
0.28
200.00%
ORKA
Oruka Therapeutics
8.61
-12.11
-58.45%
PGEN
Precigen
1.37
0.06
4.58%
RLAY
Relay Therapeutics
2.61
-3.60
-57.97%
OPT
Opthea Limited Sponsored ADR
3.20
-0.20
-5.88%
MNMD
Mind Medicine
5.46
-4.07
-42.71%
Elite Pharmaceuticals Earnings Call Summary
Earnings Call Date: Feb 13, 2025 | % Change Since: -23.64% | Next Earnings Date: Jul 7, 2025
Earnings Call Sentiment Positive
The earnings call demonstrated strong revenue and profit growth, supported by a robust pipeline and strategic facility expansion, though some supply chain challenges and financial liabilities were noted.Highlights
Record Revenue Growth
Total revenues for the quarter were $18.9 million, a $4.7 million or 33% increase from the previous year's quarter. Year-to-date revenues were $37.7 million, a $14.5 million or 63% increase compared to the previous year.
Significant Profit Increase
Operating income was $3.5 million for the quarter and $7.3 million for the six months, representing an 81% increase quarter-to-quarter and a 108% increase year-to-date compared to last year.
Strong Cash Flow Position
Operating cash flow for the six months ended September 2024 was a positive $4.6 million, a $7.5 million turnaround from the previous year's negative $2.9 million.
Pipeline Expansion
New product launches included methotrexate and Codeine APAP, with upcoming launches of hydrocodone and APAP, Oxy/APAP, and methadone. A pending ANDA approval for a central nervous system product is expected soon.
Facility Expansion
A new 35,000 square foot packaging and warehouse facility has been completed, tripling existing warehouse space and quadrupling controlled substance vault capacity.
Lowlights
API Supply Challenges
Launch of Oxy/APAP was delayed due to API supply particle size issues, indicating potential supply chain vulnerabilities.
Naltrexone API Shortage
Naltrexone API is in short supply, limiting product availability for both Elite and the rest of the industry.
Derivative Liability Increase
Derivative liabilities related to warrants increased by $13 million, primarily due to a rise in the company's stock price.
Company Guidance
During the Elite Pharmaceuticals Q2 2025 earnings call, the company reported a robust financial performance with total revenues reaching $18.9 million for the quarter, marking a 33% increase from the previous year's same quarter, and $37.7 million for the first six months, reflecting a 63% year-over-year growth. Operating income also saw significant growth, with $3.5 million for the quarter and $7.3 million for the six months, representing an 81% and 108% increase respectively compared to last year. The company highlighted its strong cash flow, with a positive $4.6 million operating cash flow compared to a $2.9 million cash burn in the previous year, indicating a $7.5 million turnaround. Elite's working capital improved to $32.4 million, an increase of $5.5 million since March 31, 2024. The company's pipeline remains robust with several upcoming product launches, including hydrocodone with APAP, oxycodone with APAP, and methadone, and a significant CNS ANDA pending FDA approval. Elite’s balance sheet continues to strengthen with a $9.6 million cash reserve as of September 30, up by $2.5 million from March 31.Elite Pharmaceuticals Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Elite Pharmaceuticals Expands with New Northvale Facility
Positive
Mar 3, 2025
On March 3, 2025, Elite Pharmaceuticals announced the shipment of its first lot of finished product from its new FDA-approved expanded campus in Northvale, New Jersey. This new facility includes advanced packaging technology, significantly increasing the company’s production capacity and allowing it to meet projected packaging demand for the next five years. This expansion is expected to enhance Elite’s operational capabilities and strengthen its position in the pharmaceutical industry.
Business Operations and StrategyFinancial Disclosures
Elite Pharmaceuticals Reports Q3 2025 Revenue Decline
Negative
Feb 13, 2025
Elite Pharmaceuticals reported a decrease in consolidated revenues and operating profits for the third quarter of fiscal year 2025, which ended on December 31, 2024. The revenues were $14.4 million, down 8% from the previous year, and operating profits fell by 69% to $1.1 million. These results were impacted by shipment delays due to timing differences during the holiday period. A conference call is scheduled to discuss these results and recent business developments.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.